Neuphoria Therapeutics Other Current Assets

Neuphoria Therapeutics's other current assets stands at $390K as of June 2026. That compares with $820M in the prior-year period — down 100.0% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Neuphoria Therapeutics reported $390K in other current assets versus $820M a year earlier — a 100.0% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $820M in the prior-year period — down 100.0% year over year. Sustained growth in other current assets can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Neuphoria Therapeutics's other current assets evolved across reporting periods, while the comparison chart places NEUP next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, other current assets is commonly used to spot outliers. Neuphoria Therapeutics's reading of $390K is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.